Advertisement

Current Gastroenterology Reports

, Volume 4, Issue 1, pp 37–44 | Cite as

Use of ursodeoxycholic acid in patients with liver disease

  • Paul Angulo
Article

Abstract

Ursodeoxycholic acid (UDCA), the 7β-epimer of chenodeoxycholic acid, has multiple hepatoprotective activities. UDCA modifies the bile acid pool, decreasing levels of endogenous, hydrophobic bile acids while increasing the proportion of nontoxic hydrophilic bile acids. UDCA has a choleretic effect, increasing hepatocellular bile acid excretion, as well as cytoprotective, antiapoptotic, and immunomodulatory properties. UDCA has been shown to delay development of gastroesophageal varices and progression to cirrhosis as well as to improve long-term survival in patients with primary biliary cirrhosis. Significant improvement of abnormal liver tests may be achieved during UDCA therapy in patients with primary sclerosing cholangitis, intrahepatic cholestasis of pregnancy, cystic fibrosis-associated liver disease, nonalcoholic fatty liver disease, graft-versus-host disease of the liver, total parenteral nutrition-induced cholestasis, and in some pediatric cholestatic liver diseases. However, unlike the effecs of UDCA in primary biliary cirrhosis, the long-term effects of UDCA in disease progression and survival in these other conditions remain to be established.

Keywords

Bile Acid Primary Biliary Cirrhosis Cholestasis Primary Sclerosing Cholangitis Ursodeoxycholic Acid 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References and Recommended Reading

  1. 1.
    Iwasaki T: Uber die konstitution der urso-deoxycholsaure. Z Physiol Chem 1936, 244:181–193.Google Scholar
  2. 2.
    Makino I, Shinozaki K, Yoshino K, Nakagawa S: Dissolution of cholesterol gallstones by long-term administration of ursodeoxycholic acid. Jpn J Gastroenterol 1975, 72:690–702.Google Scholar
  3. 3.
    Leuschner U, Leuschner M, Sieratzki J, et al.: Gallstone dissolution with ursodeoxycholic acid in patients with chronic active hepatitis and two year follow-up: a pilot study. Dig Dis Sci 1985, 30:642–649.PubMedCrossRefGoogle Scholar
  4. 4.
    Poupon R, Chretien Y, Poupon RE, et al.: Is ursodeoxycholic acid an effective treatment for primary biliary cirrhosis? Lancet 1987, 1:834–836.PubMedCrossRefGoogle Scholar
  5. 5.
    Trauner M, Graziadei IW: Mechanism of action and therapeutic applications of ursodeoxycholic acid in chronic liver diseases. Aliment Pharmacol Ther 1999, 13:979–995. Outstanding review of the history, mechanisms of action, and therapeutic use of UDCA.PubMedCrossRefGoogle Scholar
  6. 6.
    Lazaridis KN, Gores JG, Lindor KD: Ursodeoxycholic acid ‘mechanisms of action and clinical use in hepatobiliary disorders’. J Hepatol 2001, 35:134–146. Like the paper by Trauner et al., this paper represents an excellent review of the history and mechanisms of action of UDCA as well as an update of the multiple clinical studies reported in the literature evaluating UDCA as a therapy for hepatobiliary disorders.PubMedCrossRefGoogle Scholar
  7. 7.
    Hofmann AF: Pharmacology of ursodeoxycholic acid, an enterohepatic drug. Scand J Gastroenterol 1994, 29(suppl204):1–15.Google Scholar
  8. 8.
    Rodrigues CMP, Fan G, Wong PY, et al.: Ursodeoxycholic acid may inhibit deoxycholic acid-induced apoptosis by modulating mitochondrial transmembrane potential and reactive oxygen species production. Mol Med 1998, 4:165–178.PubMedCrossRefGoogle Scholar
  9. 9.
    Rodrigues CMP, Fan G, Ma X, et al.: A novel role for ursodeoxycholic acid in inhibiting apoptosis by modulating mitochondrial membrane perturbation. J Clin Invest 1998, 101:2790–2799.PubMedGoogle Scholar
  10. 10.
    Podevin P, Calmus Y, Bonnefis MT, et al.: Effect of cholestasis and bile acids on interferon-induced 2′,5′-adenylate synthesis and NK cell activities. Gastroenterology 1995, 108:1192–1198.PubMedCrossRefGoogle Scholar
  11. 11.
    Calmus Y, Gane P, Rouger P, et al.: Hepatic expression of class I and class II major histocompatibility complex molecules in primary biliary cirrhosis: effect of ursodeoxycholic acid. Hepatology 1990, 11:12–15.PubMedCrossRefGoogle Scholar
  12. 12.
    Terasaki S, Nikamura Y, Ogine H, et al.: Hepatocellular and biliary expression of HLA antigens in primary biliary cirrhosis before and after ursodeoxycholic acid therapy. Am J Gastroenterol 1991, 86:1194–1199.PubMedGoogle Scholar
  13. 13.
    Nishigaki Y, Ohnishi H, Moriwaki H, et al.: Ursodeoxycholic acid corrects defective natural killer activity by inhibiting prostaglandin E2 production in primary biliary cirrhosis. Dig Dis Sci 1996, 41:1487–1493.PubMedCrossRefGoogle Scholar
  14. 14.
    Yamazaki K, Suzuki K, Nakamura A, et al.: Ursodeoxycholic acid inhibits eosinophil degranulation in patients with primary biliary cirrhosis. Hepatology 1999, 30:71–78. This study demonstrates that, in patients with primary biliary cirrhosis, 4-week treatment with UDCA decreases peripheral blood eosinophil levels and inhibits eosinophilic activation and degranulation.PubMedCrossRefGoogle Scholar
  15. 15.
    Fiorucci S, Mancarelli A, Palazzetti B, et al.: An NO derivative of ursodeoxycholic acid protects against Fas-mediated liver injury by inhibiting caspase activity. Proc Natl Acad Sci U S A 2001, 98:2652–2657. This study shows that NCX-1000, a nitric oxide derivative of UDCA, protects against liver damage in murine models of autoimmune hepatitis induced by intravenous injection of Con A or a Fas agonistic antibody, Jo2. Through NCX-1000, UDCA protected against T helper 1-mediated liver injury by inhibiting both the proapoptotic and the proinflammatory branches of the caspase superfamily.PubMedCrossRefGoogle Scholar
  16. 16.
    Jazrawi RP, DeCaestecker JS, Goggin PM, et al.: Kinetics of hepatic bile acids handling in cholestatic liver disease: effect of ursodeoxycholic acid. Gastroenterology 1994, 106:134–142.PubMedGoogle Scholar
  17. 17.
    Medina JF, Martinez-Anso E, Vazquez JJ, et al.: Decreased anion exchanger 2 immunoreactivity in the liver of patients with primary biliary cirrhosis. Hepatology 1997, 25:12–17.PubMedCrossRefGoogle Scholar
  18. 18.
    Shimokura GH, McGill JM, Schlenker T, et al.: Ursodeoxycholate increases cytosolic calcium concentration and activates Cl-currents in a biliary cell line. Gastroenterology 1995, 109:965–972.PubMedCrossRefGoogle Scholar
  19. 19.
    Nathanson MH, Burgstahler AD, Masyuk A, et al.: Stimulation of ATP secretion in the liver by therapeutic bile acids. Biochem J 2001, 358:1–5.PubMedCrossRefGoogle Scholar
  20. 20.
    Dumont M, Erlinger S, Uchman S: Hypercholeresis induced by ursodeoxycholic acid and 7-ketolitho-cholic acid in the rat: possible role of bicarbonate transport. Gastroenterology 1980, 79:82–89.PubMedGoogle Scholar
  21. 21.
    Poupon RE, Balkau B, Eschwege E, et al.: A multicenter, controlled trial of ursodiol for the treatment of primary biliary cirrhosis. N Engl J Med 1991, 324:1548–1554.PubMedCrossRefGoogle Scholar
  22. 22.
    Lindor KD, Dickson ER, Baldus WP, et al.: Ursodeoxycholic acid in the treatment of primary biliary cirrhosis. Gastroenterology 1994, 106:1284–1290.PubMedGoogle Scholar
  23. 23.
    Heathcote EJ, Cauch-Dudek K, Walker V, et al.: The Canadian multicenter double-blind randomized controlled trial of ursodeoxycholic acids in primary biliary cirrhosis. Hepatology 1994, 19:1149–1156.PubMedCrossRefGoogle Scholar
  24. 24.
    Combes B, Carithers RL, Maddrey WC, et al.: A randomized, double-blind, placebo-controlled trial of ursodeoxycholic acid in primary biliary cirrhosis. Hepatology 1995, 22:759–766.PubMedGoogle Scholar
  25. 25.
    Pares A, Caballeria L, Rodes J, et al.: Long-term effects of ursodeoxycholic acid in primary biliary cirrhosis: results of a double-blind controlled multicentric trial. J Hepatol 2000, 32:561–566.PubMedCrossRefGoogle Scholar
  26. 26.
    Angulo P, Batts KP, Therneau TM, et al.: Long-term ursodeoxycholic acid delays histologic progression in primary biliary cirrhosis. Hepatology 1999, 29:644–647. This study shows that UDCA (13 to 15 mg/kg/d), given for 5 years or longer, significantly reduces the rate of progression to the cirrhotic stage in patients with primary biliary cirrhosis.PubMedCrossRefGoogle Scholar
  27. 27.
    Corpechot C, Carrat F, Bonnard AM, et al.: The effect of ursodeoxycholic acid on liver fibrosis progression in primary biliary cirrhosis. Hepatology 2000, 32:1196–1199. This study shows that UDCA (13 to 15 mg/kg/d), given for up to 4 years, significantly reduces the overall rate of fibrosis progression in patients with primary biliary cirrhosis.PubMedCrossRefGoogle Scholar
  28. 28.
    Goulis J, Leandro G, Burroughs AK: Randomized controlled trials of ursodeoxycholic acid therapy for primary biliary cirrhosis: a meta-analysis. Lancet 1999, 354:1053–1060. This meta-analysis questions the beneficial effect of UDCA in prolonging long-term survival in patients with primary biliary cirrhosis. The credibility of this meta-analysis has been seriously questioned, given the high level of heterogeneity of studies pooled for analysis.PubMedCrossRefGoogle Scholar
  29. 29.
    Lindor KD, Poupon R, Poupon RE, et al.: Ursodeoxycholic acid for primary biliary cirrhosis. Lancet 2000, 355:657–658. This report analyzes critically the multiple methodologic flaws of a meta-analysis (Goulis et al.) of UDCA in primary biliary cirrhosis.PubMedCrossRefGoogle Scholar
  30. 30.
    Angulo P, Dickson ER, Therneau TM, et al.: Comparison of three doses of ursodeoxycholic acid in the treatment of primary biliary cirrhosis: a randomized trial. J Hepatol 1999, 30:830–835.PubMedCrossRefGoogle Scholar
  31. 31.
    Pasha T, Heathcote J, Gabriel S, et al.: Cost-effectiveness of ursodeoxycholic acid therapy in primary biliary cirrhosis. Hepatology 1999, 29:21–26.PubMedCrossRefGoogle Scholar
  32. 32.
    Poupon R, Lindor KD, Cauch-Dudek K, et al.: Combined analysis of French, American and Canadian randomized controlled trials of ursodeoxycholic acid therapy in primary biliary cirrhosis. Gastroenterology 1997, 113:884–890.PubMedCrossRefGoogle Scholar
  33. 33.
    Angulo P, Jorgensen RA, Lindor KD: Incomplete response to ursodeoxycholic acid in primary biliary cirrhosis: is a double dosage worthwhile? Am J Gastroenterol 2001, 96:3152–3157.PubMedCrossRefGoogle Scholar
  34. 34.
    Lindor KD: Ursodiol for primary sclerosing cholangitis. N Engl J Med 1997, 336:691–695.PubMedCrossRefGoogle Scholar
  35. 35.
    Harnois DM, Angulo P, Jorgensen RA, et al.: High-dose ursodeoxycholic acid as a therapy for patients with primary sclerosing cholangitis. Am J Gastroenterol 2001, 96:1558–1562. This provocative study suggests that, in patients with primary sclerosing cholangitis, a double dosage of UDCA (25 to 30 mg/kg/d) is necessary to see a benefit in long-term survival. Based on these results, a large-scale, placebo-controlled trial has been initiated in the United States.PubMedCrossRefGoogle Scholar
  36. 36.
    Tung BY, Emond MJ, Haggitt RC, et al.: Ursodiol use is associated with lower prevalence of colonic neoplasia in patients with ulcerative colitis and primary sclerosing cholangitis. Ann Intern Med 2001, 134:89–95. This study provides important evidence to support the hypothesis that UDCA may protect against the development of colorectal cancer in patients with ulcerative colitis and primary sclerosing cholangitis. The investigators found a negative association between UDCA use and high-grade dysplasia (adjusted odds ratio, 0.16; 95% CI, 0.03 to 0.96).PubMedGoogle Scholar
  37. 37.
    Palma J, Reyes H, Ribalta J, et al.: Ursodeoxycholic acid in the treatment of cholestasis of pregnancy: a randomized, double-blind study controlled with placebo. J Hepatol 1997, 27:1022–1028.PubMedCrossRefGoogle Scholar
  38. 38.
    Mazzella G, Rizzo N, Azzaroli F, et al.: Ursodeoxycholic acid administration in patients with cholestasis of pregnancy: effects on primary bile acids in babies and mothers. Hepatology 2001, 33:504–508.PubMedCrossRefGoogle Scholar
  39. 39.
    Lindblad A, Glaumman H, Strandvik B: A 2-year prospective study of the effect of ursodeoxycholic acid on urinary bile acids excretion and liver morphology in cystic fibrosisassociated liver disease. Hepatology 1998, 27:166–174.PubMedCrossRefGoogle Scholar
  40. 40.
    Van de Meeberg PC, Houwen RH, Sinaasappel M, et al.: Low-dose versus high-dose ursodeoxycholic acid in cystic fibrosis-related cholestatic liver disease: results of a randomized study with 1-year follow-up. Scand J Gastroenterol 1997, 32:369–373.PubMedCrossRefGoogle Scholar
  41. 41.
    Jacquemin E, Hermans D, Myara A, et al.: Ursodeoxycholic acid therapy in pediatric patients with progressive familial intrahepatic cholestasis. Hepatology 1997, 25:519–523.PubMedCrossRefGoogle Scholar
  42. 42.
    Ullrich D, Rating D, Schroter W, et al.: Treatment with ursodeoxycholic acid renders children with biliary atresia suitable for liver transplantation. Lancet 1987, 2:1324.PubMedCrossRefGoogle Scholar
  43. 43.
    Tint GS, Salen G, Colalillo A, et al.: Ursodeoxycholic acid: a safe and effective agent for dissolving cholesterol gallstones. Ann Intern Med 1982, 97:351–731.PubMedGoogle Scholar
  44. 44.
    Angulo P, Lindor KD: Management of nonalcoholic fatty liver: present and emerging therapies. Semin Liver Dis 2001, 21:81–88.PubMedCrossRefGoogle Scholar
  45. 45.
    Laurin J, Lindor KD, Crippin JS, et al.: Ursodeoxycholic acid or clofibrate in the treatment of non-alcoholic induced steatohepatitis. Hepatology 1996, 23:1464–1467.PubMedCrossRefGoogle Scholar
  46. 46.
    Plevris JN, Hayes PC, Bouchier IAD: Ursodeoxycholic acid in the treatment of alcoholic liver disease. Eur J Gastroenterol Hepatol 1991, 3:653–6556.Google Scholar
  47. 47.
    Spangnuolo MI, Iorio R, Vegnente A, et al.: Ursodeoxycholic acid for treatment of cholestasis in children on long-term total parenteral nutrition: a pilot study. Gastroenterology 1996, 111:716–719.CrossRefGoogle Scholar
  48. 48.
    Essell JH, Schroeder MT, Harman GS, et al.: Ursodiol prophylaxis against hepatic complications of allogeneic bone marrow transplantation: a randomized, double-blind, placebo-controlled trial. Ann Intern Med 1998, 128:975–981.PubMedGoogle Scholar
  49. 49.
    Barnes D, Talenti D, Cammell G, et al.: A randomized clinical trial of prophylaxis of ursodeoxycholic acid as adjuvant treatment to prevent liver transplantation rejection. Hepatology 1997, 26:853–857.PubMedCrossRefGoogle Scholar
  50. 50.
    Pageaux GP, Blanc P, Perrigault PF, et al.: Failure of ursodeoxycholic acid to prevent acute cellular rejection after liver transplantation. J Hepatol 1995, 23:119–122.PubMedCrossRefGoogle Scholar
  51. 51.
    Keiding S, Hockerstedt K, Bjoro K, et al.: The Nordic multicenter double-blind randomized controlled trial of prophylactic of ursodeoxycholic acid in liver transplant patients. Transplantation 1997, 63:1591–1594.PubMedCrossRefGoogle Scholar
  52. 52.
    Fleckenstein JF, Paredes M, Thuluvath PJ: A prospective, randomized, double-blind trial evaluating the efficacy of ursodeoxycholic acid in prevention of liver transplant rejection. Liver Transplant Surg 1998, 4:276–279.CrossRefGoogle Scholar
  53. 53.
    Bonkovsky HL: Therapy of hepatitis C: other options. Hepatology 1997, 26(suppl1):S143-S151.CrossRefGoogle Scholar
  54. 54.
    Nakamura K, Yoneda M, Yokohama S, et al.: Efficacy of ursodeoxycholic acid in Japanese patients with type 1 autoimmune hepatitis. J Gastroenterol Hepatol 1998, 12:490–495.Google Scholar
  55. 55.
    Czaja AJ, Carpenter HA, Lindor KD: Ursodeoxycholic acid as adjuvant therapy for problematic type 1 autoimmune hepatitis: a randomized, placebo-controlled treatment trial. Hepatology 1999, 30:1381–1386.PubMedCrossRefGoogle Scholar

Copyright information

© Current Science Inc 2002

Authors and Affiliations

  • Paul Angulo
    • 1
  1. 1.Division of Gastroenterology and HepatologyMayo Clinic and FoundationRochesterUSA

Personalised recommendations